Physician profile
Elias E Dabul
NPI 1669440129
$5,172.86
in general payments reported to CMS, 2019-2025
29 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $451 · 2021: $813 · 2022: $332 · 2023: $423 · 2024: $876 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,090.19 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $444.37 | 2019-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $366.46 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $365.77 | 2019-2024 | |
| Micro-Tech Endoscopy USA, INC. | $325.16 | 2022-2025 | Eyemax, Valve Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $278.81 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $247.60 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $228.11 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $190.48 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.44 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Redhill Biopharma INC. | $166.91 | 2020-2022 | |
| Ardelyx, INC. | $163.62 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $162.41 | 2023 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $152.52 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $121.02 | 2024-2025 | Zenpep |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $114.77 | 2019-2022 | |
| Genzyme Corporation | $88.30 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.45 | 2023-2025 | Dupixent |
| Evoke Pharma, INC. | $76.45 | 2020-2025 | |
| Allergan, INC. | $57.77 | 2019-2020 | |
| Lilly USA, LLC | $50.10 | 2024-2025 | Omvoh |
| Shionogi INC | $46.04 | 2019 | |
| Intercept Pharmaceuticals, INC. | $35.05 | 2019-2025 | |
| Braintree Laboratories, INC. | $33.48 | 2020 | |
| Davol INC. | $25.22 | 2020 | |
| Amgen INC. | $25.08 | 2021 | |
| Celltrion USA INC. | $24.70 | 2025 | Vegzelma |
| Qol Medical, LLC | $18.33 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.25 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Dabul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.